About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Health Care and Law
The author reviews the recent progress in the area of stem cell technology and discusses the obstacles to further development in the U.S..
Robert I. Field, JD, MPH, PhD
Three antineoplastic agents are described: intravenous cetuximab for metastatic colorectal cancer, injected pemetrexed for malignant pleural mesothelioma, and injected oxaliplatin for recurrent or metastatic colorectal cancer.
Marvin M. Goldenberg, PhD, RPh, MS
Dr. Howden reviews tegaserod maleate (Zelnorm™) and its role in patients with multiple gastrointestinal problems.
Colin W. Howden, MD
Pharmacists respond to a nationwide survey about their likes and dislikes on the job.
Vittorio Maio, PharmD, MS, Neil I. Goldfarb, and Christine W. Hartmann, MSS
Dr. Prescott reports on a combined thrombolytic/glycoprotein receptor blocker
therapy for middle cerebral artery occlusion, a thrombin inhibitor, a low-dose thrombolytic agent, an astrocyte activation modulator, a new investigational agent, amphetamine therapy plus physiotherapy, statins for brain infarction, and recombinant factor VIIa for correcting warfarin anticoagulation.
Lawrence M. Prescott, PhD
David Nash, MD, MBA, discusses articles that followed up on themes in earlier P&T editorials on ALLHAT and counterfeit drugs.
David Nash, MD, MBA
Editorial Board Spotlight
Matthew Grissinger discusses his background in pharmacy and his role at the Institute for Safe Medication Practices.
Stephen Barlas comments on the FDA’s draft guidance calling for clearer language in the “brief” summaries in drug package inserts.
Matthew Grissinger, RPh, FASCP, describes a mix-up that occurred when sodium acetate was confused with potassium acetate.
Matthew Grissinger, RPh, FASCP
Yvonne Ho and Larisa Chagan review memantine
(Namenda™) for moderate-to-severe Alzheimer’s disease.
Yvonne Ho, PharmD Candidate, and Larisa Chagan, BS, PharmD, BCPS